Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-29

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis is that in patients with emphysema, a high MMP12 sputum and/or blood level correlates with airspace enlargement and with increased sputum Th2 immune biomarkers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease

NCT03455686

Asthma Chronic Obstructive Pulmonary Disease Bronchiectasis +5 more

RECRUITING NA

Biomarkers and Genetic Factors Related to Emphysema

NCT00757120

Emphysema Pulmonary Disease, Chronic Obstructive

COMPLETED

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490

Asthma COPD Interstitial Lung Disease +4 more

RECRUITING PHASE1

Xenon-129 and Inert Fluorinated Gas Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease

NCT02740868

Cystic Fibrosis Asthma

RECRUITING PHASE2

Lung Structure-Function In Survivors of Mild and Severe COVID-19 Infection

NCT04584671

Covid19

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since MMP-12 apparently has a preponderant role in the genesis of emphysema and probably in airspace enlargement, its inhibition may result in an interesting targeting point in view to find specific therapies in obstructive diseases. There is abundant evidence in animal models that shows how MMP-12 blockade inhibits the development of emphysema and airway remodeling. Unfortunately, the results have not been conclusive in human models.

In the last years, pulmonary imaging biomarkers that measure airspace enlargement have been developed. In particular, the apparent diffusion coefficient (ADC), quantified by inhaled hyperpolarized gas MRI, reflects alveolar airspace size. ADC provides information consistent with histopathological findings that may be used to estimate lung disease progression and treatment response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Emphysema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with emphysema and eosinophilia in blood and sputum

blood eosinophils ≥300 cells/μL and sputum eosinophils \>3%

Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI

Intervention Type PROCEDURE

Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds

Patients with emphysema and paucicellular inflammation

sputum neutrophils \<65% and eosinophils \<3%

Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI

Intervention Type PROCEDURE

Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds

Patients with emphysema and sputum neutrophilia

sputum neutrophils \>65% and sputum eosinophils \< 3%

Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI

Intervention Type PROCEDURE

Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI

Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥40 years of age
* Current or ex-smokers with a \>10 pack year smoking history
* Have a post-bronchodilator forced expired volume in 1 second (FEV1)/forced expired vital capacity (FVC) ratio of \<70% and a post-bronchodilator FEV1 value from ≥30% predicted (GOLD 1, 2 and 3), (Global Initiative for Obstructive Lung disease)
* Have a radiologist confirmed pulmonary emphysema diagnosis based on CT

* No clinically significant medical condition or a history of asthma, COPD, cystic fibrosis, or other significant respiratory disorder including significant occupational or environmental exposures with ongoing respiratory symptoms.
* No current or past smoking history
* Have a post-bronchodilator FEV1/FVC ratio of \>70%

Exclusion Criteria

Any potential subject who meets any of the following criteria will be excluded from participating in the study:

* Patients with other non-COPD airway diseases
* Patients with very severe COPD (FEV1\<30% predicted)
* Patients with an intercurrent exacerbation
* Patients with life expectancy less than 3 months
* Pregnant or breastfeeding
* Undergoing immunomodulatory or biologic treatment
* Use of systemic steroids in the last month
* Hospitalization in the last 12 months due to exacerbation
* Known cardiovascular comorbidity under treatment or with hospitalizations of this cause in the last year
* That they cannot perform spirometry
* Active malignancy
* Realization of lung surgery during the study period
* History of alcohol and drug abuse that prevents compliance with follow-up
* History of bronchial thermoplasty
* Participating in another study concomitantly
* MRI Related: patients who have implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, artificial limb, metallic fragments of foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants).

Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No